

24. – 25. MAI 2016

Schloß Schönbrunn, Wien
Apothekertrakt und Orangerie

PREDICTIVE MODELING IN
HEALTHCARE –
**FROM PREDICTION
TO PREVENTION**

www.ehealthsummit.at

Präsentiert von

himss Europe

AIT
AUTOMATED INTELLIGENT
TOMORROW TODAY

 Österreichische Gesellschaft
für Biomedizinische Technik
Austrian Society for
Biomedical Engineering

 OÖSTERREICHISCHE
COMPUTER GESELLSCHAFT
AUSTRIAN
COMPUTER SOCIETY

UNIT


Big Data oder Wissen als Spezialanfertigung – Transparenz und Zuverlässigkeit

Klaus-Peter Adlassnig

Medexter Healthcare
Borschkegasse 7/5, A-1090 Vienna
www.medexter.com

and


Section for Artificial Intelligence and Decision Support
Center for Medical Statistics, Informatics, and Intelligent Systems
Medical University of Vienna
Spitalgasse 23, A-1090 Vienna
www.meduniwien.ac.at/kpa




Digitalization of clinical medicine

- Stage I: Digitizing patient medical data
 - EHRs, EMRs, Health Apps, ...
- Stage II: Digitizing clinical workflows
 - In-patient, out-patient, home
- Stage III: Digitizing medical knowledge
 - Big data vs. knowledge design

Clinical decision support—Applying knowledge to data






- studies in Colorado and Utah and in New York (1997)
 - errors in the delivery of health care leading to the death of as many as 98,000 US citizens annually
- causes of errors
 - error or delay in diagnosis
 - failure to order indicated tests
 - use of outdated tests or therapy
 - failure to act on results of testing or monitoring
 - error in the performance of a test, procedure, or operation
 - error in administering the treatment
 - error in the dose or method of using a drug
 - avoidable delay in treatment or in responding to an abnormal test
 - failure to provide (indicated) care
 - failure in communication
 - equipment failure
- prevention of errors
 - we must systematically design safety into processes of care


Big data vs. knowledge design

IBM Watson Health vs. Medexter Health Knowledge

Big data vs. knowledge design



IBM Watson Health vs. Medexter Health Knowledge



Hepaxpert

Knowledge-based interpretation of hepatitis serology test results

Automated interpretation of hepatitis serology test results

Hepaxpert

Input of test results

Hepatitis A Serology

anti-HAV	positive	negative	borderline	not tested
IgM anti-HAV	positive	negative	borderline	not tested
HAV-RNA	positive	negative	borderline	not tested

Hepatitis B Serology

HBsAg	positive	negative	borderline	not tested
anti-HBs	positive	negative	borderline	not tested
anti-HBc	positive	negative	borderline	not tested
IgM anti-HBc	positive	negative	borderline	not tested
HBeAg	positive	negative	borderline	not tested
anti-HBe	positive	negative	borderline	not tested
anti-HBs titre	enter value between 0 and 99,999 in U/I U/I			

Hepatitis C Serology

anti-HCV	positive	negative	borderline	not tested
HCV-RNA	positive	negative	borderline	not tested

Interpretation **About**

Interpretation

Hepatitis A Serology

anti-HAV IgM anti-HAV HAV-RNA

Positive results for total anti-HAV antibodies in combination with negative results for IgM anti-HAV antibodies indicate immunity to the hepatitis virus A and exclude the possibility of a recent hepatitis A. This immunity may either have been acquired naturally through an earlier infection or it may have been induced by active vaccination or passively acquired immunization.

Hepatitis B Serology

HBsAg anti-HBs anti-HBc IgM anti-HBc HBeAg anti-HBe

anti-HBs titre

The simultaneous occurrence of HBe-antigen and anti-HBs antibodies is a rare event in the natural course of a hepatitis B virus infection. This constellation of findings may be attributed to one of the following causes: (a) circulating HBsAg-anti-HBs immune complexes, (b) hepatitis B virus infection coinciding with a hepatitis B vaccination or injection of HB-hyperimmune globulin, or (c) reinfection with a hepatitis virus B with a different HBsAg subtype. Blood and secretions (saliva, sperm, breast milk) of such patients are to be regarded as infectious. In order to obtain conclusive information on the ambiguous negative or positive result, it is recommended to have new material sent in for testing and/or to consult with the head of the laboratory.

Hepatitis C Serology

anti-HCV HCV-RNA

The findings obtained give no indication of a present or earlier hepatitis C virus infection, but these cannot be definitely excluded. In rare cases despite negative HCV antibodies HCV-RNA may be detected in the serum. Nevertheless, in practice anti-HCV-negative blood (also without information about HCV-RNA) is considered to be not infectious with regard to hepatitis C.

Back **New Input** **About**

Hepaxpert

Input of test results

Hepatitis A Serology

anti-HAV positive

IgM anti-HAV not tested

HAV-RNA not tested

Hepatitis B Serology

HBsAg negative

anti-HBs not tested

anti-HBc not tested

IgM anti-HBc negative

HBeAg not tested

anti-HBe not tested

anti-HBs titre 120 U/I

Hepatitis C Serology

anti-HCV negative

HCV-RNA not tested

Interpretation **About**

Interpretation

Hepatitis A Serology

HBsAg

anti-HBs

anti-HBc

IgM anti-HBc

HBeAg

anti-HBe

anti-HBs titre 120 U/I

This constellation of findings (positive anti-HBs antibodies, with negative IgM anti-HBc antibodies) indicates the presence of immunity to the hepatitis virus B. This immunity may either have been acquired naturally upon restitution following a hepatitis B virus infection or it may have been induced by active or passive immunization. Vaccination Recommendation: If an indication for a hepatitis B vaccination exists, the primary course of immunization has been completed, the last partial vaccination was given at least 1 month previously, and the vaccinated person's immunity is unimpaired, then a hepatitis B vaccination (or a follow-up anti-HBs titre check) within 1 year, based on the titre examination date, is to be recommended at the measured anti-HBs titre value of 120.

Back **New Input** **About**

- includes frequent, rare, as well as inconsistent combinations
- complete coverage of the problem domains
- e.g., hepatitis B serology: about 150 rules in 3 layers for 61,440 possible combinations





Diagnostisches Profil Hepatitis B

Dieser serologische Verlauf trifft bei 75 - 80% der Patienten mit akuter Hepatitis B auf.

Profil der serologischen Marker eines chronischen Trägers:

keine Serokonversion (Anti-HBe)




Serologische Marker Hepatitis B


HBV-DNA	●					
HBeAg	●					
HBsAg	●					
Anti-HBc IgM						
Anti-HBc						
Anti-HBe						
Anti-HBs						

Infektionsstatus

infektiös	●
potentiell infektiös	
wahrscheinlich nicht infektiös	
immun	



Dieser serologische Verlauf trifft bei 75 - 80% der Patienten mit akuter Hepatitis B auf.



One of the rules to interpret clinically relevant findings (rule premises form equivalent classes)

RULE 103:

IF one of the following 100 combinations

HBsAg	anti-HBs	anti-HBc	IgM anti-HBc	HBeAg	anti-HBe
+	•	+	- ± •	+	- ± •
+	•	+	+	+	+

THEN

The simultaneous occurrence of HBe-antigen and anti-HBs antibodies is a **rare event** in the natural course of a hepatitis B virus infection. This constellation of findings may be attributed to one of the following causes: (a) circulating HBsAg-anti-HBs immune complexes, (b) hepatitis B virus infection coinciding with a hepatitis B vaccination or injection of HB-hyperimmune globulin, or (c) reinfection with a hepatitis virus B with a different HBsAg subtype. Blood and secretions (saliva, sperm, breast milk) of such patients are to be regarded as infectious.

Regel zur Interpretation von „inkonsistente Befunde“

REGEL 3:

WENN

HBsAg	anti-HBs	anti-HBc	IgM anti-HBc	HBeAg	anti-HBe
+ •	+ – ± •	– ±	+	+ – ± •	– ± •
– ±	+ – ± •	– ±	+	– ± •	– ± •

DANN

Das Befundmuster enthält **Widersprüche**, da definitionsgemäß bei Vorliegen von IgM anti-HBc-Antikörpern auch die Anti-HBc-Gesamtantikörper positiv sein müssten. Neueinsendung von Untersuchungsmaterial bzw. Rücksprache mit dem Laborleiter wird empfohlen.


Monate	Anforderungen	Muster (von 4.095)		Regeln (von 105)	
0	0	0	0,0%	0	0%
1	524	25	0,6%	19	18%
2	1.084	39	1,0%	28	27%
3	1.665	52	1,3%	32	30%
4	2.169	65	1,6%	35	33%
5	2.842	75	1,8%	37	35%
6	3.402	83	2,0%	40	38%
7	4.037	87	2,1%	41	39%
8	4.559	93	2,3%	42	40%
9	5.115	98	2,4%	45	43%
10	5.624	102	2,5%	46	44%
11	6.021	103	2,5%	46	44%
12	6.399	105	2,6%	47	45%
13	6.896	112	2,7%	50	48%
14	7.575	115	2,8%	50	48%
15	8.219	118	2,9%	50	48%
16	8.699	124	3,0%	51	49%
17	9.327	129	3,2%	51	49%
18	9.890	131	3,2%	51	49%
19	10.439	134	3,3%	53	50%
20	11.303	135	3,3%	53	50%

Häufigkeit des Auftretens von Befundmustern und Regeln für die
Hepatitis B im Verlauf von 20 Monaten

Clinical alerts

Ward-specific, highly-adaptive reminders

Inflammation Monitoring and Alerts



- Dashboard
- Patients
- Laboratory
- Ambulance
- Forms
- Medication
- Reporting
- Preferences
- Mustermann, Max
- Adam, Reinhard
- Auer, Dietmar
- Bauer, Stefanie
- Berger, Anita
- Cruzcer, Karin
- Dietrich, Dominik
- Falli, Robert
- Frauenstein, Lisa
- Grutsch, Renate
- Heiter, Thomas
- Huber, Karl
- Hufnagl, Martin
- Kaindl, Laura
- Kaiser, Franz
- Kapferer, Johannes
- Lander, Simon
- Leitmayer, Sonja
- Loidl, Elisabeth
- Maier, Franz
- Maier, Sabin
- Neuwirt, Markus
- Schneider, Stefan
- Seidl, Anita
- Tauern, Barbara

Mustermann, Max

Sex: male

Age: 48

Date of Birth: 08-10-1966

NINO: 1234100866

Case Number: 468895

Hospital Admittance: 04-15-2015

Documents

Vital Signs

Laboratory

Diagnoses

Radiology

Images

References

Outside Records

04-18-2015 13:02

04-17-2015 12:52

04-16-2015 11:29

04-15-2015 13:37

HEMATOLOGICAL PROFILE

Leukocytes19,4 /nl20,1 /nl17,5 /nl17,1 /nl

Hemoglobin- - - -

...

BIOCHEMICAL PROFILE

Electrolytes

Potassium- - - -

...

Inflammation markers

C-reactive protein169 mg/l105 mg/l98 mg/l80 mg/l

...

Kidney function

Blood urea nitrogen- - - -

Serum creatinine- - - -

Urea- - - -

...

Enzymes

Troponin- - - -

...

Thyroid function

Clinical Alerts

GENERATEDMESSAGES

04-18-2015 13:02Further increase of CRP+

04-18-2015 13:02Persistent leukocytosis-

Persistent leukocytosis (19,4 /nl, 04-18-2015 13:02) compared to previous findings:

04-17-2015 12:52	Leukocytes 20,1 /nl	04-17-2015 12:52	CRP 105 mg/l
04-16-2015 11:29	Leukocytes 17,5 /nl	04-16-2015 11:29	CRP 98 mg/l
04-15-2015 13:37	Leukocytes 17,1 /nl	04-15-2015 13:37	CRP 80 mg/l

04-17-2015 12:52Further increase of leukocytes+

04-15-2015 13:37Leukocyte value indicates leukocytosis-

Leukocyte value indicates leukocytosis: 17,1 /nl (04-15-2015 13:37). Consider CRP.

04-15-2015 13:37Moderately increased CRP+

Summary

- Big data mining
 - Huge amount of data available
 - Erroneous cases are usually part of the data
 - Empirical data are incomplete
 - Low transparency
 - Big document mining
 - Huge amount of documents available
 - Documents are humanly preprocessed and checked
 - Learning from erroneous or outdated documents
 - Medium transparency
 - Knowledge design
 - Carefully designed knowledge
 - Contains explicit causal explanations
 - Includes rare and outlier cases
 - High transparency
-